Based on these data, T-DXd is currently approved for the treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting or in the (neo)adjuvant setting and have experienced disease recurrence during or within six months of completing therapy. Here, ERBB2 is linked to breast carcinoma.